The effect of simvastatin and pravastatin on arterial blood pressure, baroreflex, vasoconstrictor, and hypertensive effects of angiotensin II in Sprague-Dawley rats

Journal of the American Society of Hypertension

Volumn 8, Issue 12, 2014, Pages 863-871

  Drapala, Adrian ^a   Aleksandrowicz, Marta ^b   Zera, Tymoteusz ^a   Sikora, Mariusz ^a   Skrzypecki, Janusz ^a   Kozniewska, Ewa ^a,b   Ufnal, Marcin ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Cholesterol; hypertension; statins

Indexed keywords

ANGIOTENSIN II; HEXAMETHONIUM; PRAVASTATIN; SIMVASTATIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMORAL ARTERY; HEART RATE; HEMODYNAMICS; HYPERTENSION; IN VITRO STUDY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRESSORECEPTOR REFLEX; RAT; VASOCONSTRICTION; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; DRUG POTENTIATION; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANIMALS; BAROREFLEX; BLOOD PRESSURE; DRUG SYNERGISM; HEART RATE; HYPERTENSION; MALE; PRAVASTATIN; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; VASOCONSTRICTION;

EID: 84915795397     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2014.09.008     Document Type: Article

References (51)

1. S. Mora, and P.M. Ridker Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 97 2006 33A 41A
2. N.J. Stone, J. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, C.B. Blum, and R.H. Eckel 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 25 Suppl 2 2014 S1 S45
3. D.C. Goff Jr., D.M. Lloyd-Jones, G. Bennett, S. Coady, R.B. D'Agostino Sr., and R. Gibbons 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 25 Pt B 2014 2935 2959
4. A. Drapala, M. Sikora, and M. Ufnal Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins J Renin Angiotensin Aldosterone Syst 15 2014 250 258
5. A.C. Guyton, and J.E. Hall Textbook of medical physiology 2006 WB Saunders Co Philadelphia
6. J.P. Montani, and B.N. Van Vliet Understanding the contribution of Guyton's large circulatory model to long-term control of arterial pressure Exp Physiol 94 2009 382 388
7. J.W. Osborn Hypothesis: set-points and long-term control of arterial pressure. A theoretical argument for a long-term arterial pressure control system in the brain rather than the kidney Clin Exp Pharmacol Physiol 32 2005 384 393
8. M. Ufnal Essential hypertension: is erroneous receptor output to blame? Med Hypotheses 78 2012 454 458
9. M. Ufnal, M. Sikora, T. Zera, and E. Szczepanska-Sadowska Simvastatin reduces pressor response to centrally administered angiotensin II Am J Hypertens 23 2010 956 959
10. M. Ufnal, A. Drapala, M. Sikora, and E. Szczepanska-Sadowska Oral simvastatin reduces the hypertensive response to air-jet stress Clin Exp Pharmacol 39 2012 350 356
11. B.B. Kent, J.W. Drane, B. Blumenstein, and J.W. Manning A mathematical model to assess changes in the baroreceptor reflex Cardiology 57 1972 295 310
12. N. Glorioso, C. Troffa, F. Filigheddu, F. Dettori, A. Soro, and P.P. Parpaglia Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia Hypertension 34 1999 1281 1286
13. B.A. Golomb, J.E. Dimsdale, H.L. White, J.B. Ritchie, and M.H. Criqui Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial Arch Intern Med 168 2008 721 727
14. S. Seki, K. Hashimoto, I. Taniguchi, M. Yoshimura, and N. Takeda Effect of rosuvastatin on systemic blood pressure in patients with hypercholesterolemia Exp Clin Cardiol 17 2012 221 225
15. A.C. Sposito, A.P. Mansur, O.R. Coelho, J.C. Nicolau, and J.A. Ramires Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril) Am J Cardiol 83 1999 1497 1499 A8
16. G. Mancia, G. Parati, M. Revera, G. Bilo, A. Giuliano, and F. Veglia Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial Brit Med J 340 2010 c1197
17. M. Tonelli, F. Sacks, M. Pfeffer, F. Lopez-Jimenez, G.S. Jhangri, and G. Curhan Effect of pravastatin on blood pressure in people with cardiovascular disease J Hum Hypertens 20 2006 560 565
18. J. Owczarek, M. Jasinska, I. Wejman, U. Kurczewska, and D. Orszulak-Michalak Effects of 4-week administration of simvastatin in different doses on heart rate and blood pressure after metoprolol injection in normocholesterolaemic and normotensive rats Arch Med Sci 8 2012 17 21
19. P. Strazzullo, S.M. Kerry, A. Barbato, M. Versiero, L. D'Elia, and F.P. Cappuccio Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials Hypertension 49 2007 792 798
20. E.D. Moreira, C.T. Mostarda, I.C. Moraes-Silva, J.B. Ferreira, F. Dos Santos, and S. Lacchini Effect of simvastatin in the autonomic system is dependent on the increased gain/sensitivity of the baroreceptors Physiol Rep 1 2013 e00045
21. N. Herring, C.W. Lee, N. Sunderland, K. Wright, and D.J. Paterson Pravastatin normalises peripheral cardiac sympathetic hyperactivity in the spontaneously hypertensive rat J Mol Cell Cardiol 50 2011 99 106
22. J.M. Ledingham, and R. Laverty Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model Clin Exp Pharmacol Physiol 32 2005 76 85
23. M. Ufnal, and J. Skrzypecki Blood borne hormones in a cross-talk between peripheral and brain mechanisms regulating blood pressure, the role of circumventricular organs Neuropeptides 48 2014 65 73
24. F.H. Leenen Actions of circulating angiotensin II and aldosterone in the brain contributing to hypertension Am J Hypertens 27 2014 1024 1032
25. J.W. Osborn Jr., M.M. Skelton, and A.W. Cowley Jr. Hemodynamic effects of vasopressin compared with angiotensin II in conscious rats Am J Physiol 252 1987 H628 H637
26. N.E. Straznicky, L.G. Howes, W. Lam, and W.J. Louis Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension Am J Cardiol 75 1995 582 586
27. P.J. Neuvonen, J.T. Backman, and M. Niemi Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin Clin Pharmacokinet 47 2008 463 474
28. A. Tsuji, A. Saheki, I. Tamai, and T. Terasaki Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier J Pharmacol Exp Ther 267 1993 1085 1090
29. M. Ufnal, A. Drapala, M. Sikora, and J. Skrzypecki Simvastatin but not pravastatin reduces the hypertensive response to intracerebroventricularly infused angiotensin II FASEB J 26 2012 lb616
30. L. Gao, W. Wang, Y.L. Li, H.D. Schultz, D. Liu, and K.G. Cornish Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase Circulation 112 2005 1763 1770
31. J.A. Quion, and P.H. Jones Clinical pharmacokinetics of pravastatin Clin Pharmacokinet 27 1994 94 103
32. B. Tesfamariam, B.H. Frohlich, and R.E. Gregg Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity J Cardiovasc Physiol 34 1999 95 101
33. J.S. Sim, J.B. Dick, and A.D. Struthers Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients J Renin Angiotensin Aldosterone Syst 5 2004 109 113
34. T. Ichiki, K. Takeda, T. Tokunou, N. Iino, K. Egashira, and H. Shimokawa Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells Arterioscler Thromb Vasc Biol 21 2001 1896 1901
35. S. Wassmann, U. Laufs, A.T. Baumer, K. Müller, C. Konkol, and H. Sauer Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase Mol Pharmacol 59 2001 646 654
36. O. Grip, S. Janciauskiene, and S. Lindgren Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes Inflamm Res 51 2002 58 62
37. I. Zelvyte, R. Dominaitiene, M. Crisby, and S. Janciauskiene Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro Pharmacol Res 45 2002 147 154
38. K. Takeda, T. Ichiki, T. Tokunou, Y. Funakoshi, N. Iino, and K. Hirano Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells Circulation 102 2000 1834 1839
39. A.M. Castejon, E. Zollner, A.G. Tristano, and L.X. Cubeddu Upregulation of angiotensin II-AT1 receptors during statin withdrawal in vascular smooth muscle cells J Cardiovasc Pharm 50 2007 708 711
40. M. Ruperez, R. Rodrigues-Diez, L.M. Blanco-Colio, E. Sánchez-López, J. Rodríguez-Vita, and V. Esteban HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways Hypertension 50 2007 377 383
41. S. Wassmann, U. Laufs, K. Muller, C. Konkol, K. Ahlbory, and A.T. Bäumer Cellular antioxidant effects of atorvastatin in vitro and in vivo Arterioscl Throm Vas 22 2002 300 305
42. M. Lunder, L. Ziberna, M. Janic, A. Jerin, M. Skitek, and M. Sabovič Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta Heart Vessels 28 2013 246 254
43. M. Kassan, M.J. Montero, and M.A. Sevilla Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats Br J Pharmacol 158 2009 541 547
44. D.G. Bezerra, and C.A. Mandarim-de-Lacerda Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats Clin Sci (Lond) 108 2005 349 355
45. I.J. Scheffers, A.A. Kroon, J. Schmidli, J. Jordan, J.J. Tordoir, and M.G. Mohaupt Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study J Am Coll Cardiol 56 2010 1254 1258
46. T.E. Lohmeier, R. Iliescu, T.M. Dwyer, E.D. Irwin, A.W. Cates, and M.A. Rossing Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex Am J Physiol Heart Circ Physiol 299 2010 H402 H409
47. M.W. Chapleau, J.T. Cunningham, M.J. Sullivan, R.E. Wachtel, and F.M. Abboud Structural versus functional modulation of the arterial baroreflex Hypertension 26 1995 341 347
48. M. Sinski, J. Lewandowski, A. Ciarka, J. Bidiuk, P. Abramczyk, and A. Dobosiewicz Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension Kardiol Pol 67 2009 613 620
49. R.U. Pliquett, K.G. Cornish, J.D. Peuler, and I.H. Zucker Simvastatin normalizes autonomic neural control in experimental heart failure Circulation 107 2003 2493 2498
50. B. Casadei, and D.J. Paterson Should we still use nitrovasodilators to test baroreflex sensitivity? J Hypertens 18 2000 3 6
51. R.B. D'Agostino Sr., B.J. Ansell, S. Mora, and H.M. Krumholz Clinical decisions. The guidelines battle on starting statins N Engl J Med 370 2014 1652 1658